```
============================================================
Sequence Listing was accepted with existing errors.
See attached Validation Report.
If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).
Reviewer: Anne Corrigan
Timestamp: Thu Jul 26 16:44:24 EDT 2007
============================================================
```

Validated By CRFValidator v 1.0.2

Application No: 10539828   Version No: 1.1

Input Set:

Output Set:

                    Started: 2007-07-26 16:44:12.142
                   Finished: 2007-07-26 16:44:12.307
                    Elapsed: 0 hr(s) 0 min(s) 0 sec(s) 165 ms
            Total Warnings: 1
              Total Errors: 1
      No. of SeqIDs Defined: 5
        Actual SeqID Count: 5

Error code   Error Description

E   287   Invalid WIPO ST.2 date format; Use (YYYY-MM-DD)in <151>

W   213   Artificial or Unknown found in <213> in SEQ ID (5)

<110> INNATE PHARMA

<120> Pharmaceutical Compositions Having an Effect on the
      Proliferation of NK Cells and a Method Using the Same

<130> B0207WO

<140> 10539828
<141> 2007-07-09

<150> US 60/435,344
<151> 23/12/2003

<160> 5

<170> PatentIn Ver. 2.1

<210> 1
<211> 190
<212> PRT
<213> Homo sapiens

<400> 1
Met Ala Trp Met Leu Leu Leu Ile Leu Ile Met Val His Pro Gly Ser
 1   5   10   15

Cys Ala Leu Trp Val Ser Gln Pro Pro Glu Ile Arg Thr Leu Glu Gly
            20   25   30

Ser Ser Ala Phe Leu Pro Cys Ser Phe Asn Ala Ser Gln Gly Arg Leu
            35   40   45

Ala Ile Gly Ser Val Thr Trp Phe Arg Asp Glu Val Val Pro Gly Lys
        50   55   60

Glu Val Arg Asn Gly Thr Pro Glu Phe Arg Gly Arg Leu Ala Pro Leu
 65   70   75   80

Ala Ser Ser Arg Phe Leu His Asp His Gln Ala Glu Leu His Ile Arg
                85   90   95

Asp Val Arg Gly His Asp Ala Ser Ile Tyr Val Cys Arg Val Glu Val
            100   105   110

Leu Gly Leu Gly Val Gly Thr Gly Asn Gly Thr Arg Leu Val Val Glu
            115   120   125

Lys Glu His Pro Gln Leu Gly Ala Gly Thr Val Leu Leu Leu Arg Ala
        130   135   140

Gly Phe Tyr Ala Val Ser Phe Leu Ser Val Ala Val Gly Ser Thr Val
145   150   155   160

Tyr Tyr Gln Gly Lys Cys His Cys His Met Gly Thr His Cys His Ser
                165   170   175

Ser Asp Gly Pro Arg Gly Val Ile Pro Glu Pro Arg Cys Pro
            180   185   190

<210> 2
<211> 120
<212> PRT
<213> Homo sapiens

<400> 2
Leu Trp Val Ser Gln Pro Pro Glu Ile Arg Thr Leu Glu Gly Ser Ser
  1   5   10   15

Ala Phe Leu Pro Cys Ser Phe Asn Ala Ser Gln Gly Arg Leu Ala Ile
            20   25   30

Gly Ser Val Thr Trp Phe Arg Asp Glu Val Val Pro Gly Lys Glu Val
            35   40   45

Arg Asn Gly Thr Pro Glu Phe Arg Gly Arg Leu Ala Pro Leu Ala Ser
        50   55   60

Ser Arg Phe Leu His Asp His Gln Ala Glu Leu His Ile Arg Asp Val
 65   70   75   80

Arg Gly His Asp Ala Ser Ile Tyr Val Cys Arg Val Glu Val Leu Gly
                85   90   95

Leu Gly Val Gly Thr Gly Asn Gly Thr Arg Leu Val Val Glu Lys Glu
            100   105   110

His Pro Gln Leu Gly Ala Gly Thr
            115   120

<210> 3
<211> 19
<212> PRT
<213> Homo sapiens

<400> 3
Val Leu Leu Leu Arg Ala Gly Phe Tyr Ala Val Ser Phe Leu Ser Val
  1   5   10   15

Ala Val Gly

<210> 4
<211> 33
<212> PRT
<213> Homo sapiens

<400> 4
Ser Thr Val Tyr Tyr Gln Gly Lys Cys His Cys His Met Gly Thr His
  1   5   10   15

Cys His Ser Ser Asp Gly Pro Arg Gly Val Ile Pro Glu Pro Arg Cys
                20   25   30

Pro

<210> 5
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: peptide derived
      from natural sequence, useful for antiserum
      production

<400> 5
Trp Val Ser Gln Pro Pro Glu Ile Arg Thr Leu Glu Gly Ser Cys
  1   5   10   15